Trial Profile
Optimized efficiency and reduced toxicity therapy of metastatic colorectal cancer in the first-line therapy [Effektivitätsoptimierte und toxizitätsreduzierte Therapie des metastasierten Kolorektalkarzinoms in der First-line Therapie]
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 21 Oct 2014
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- Acronyms ERBIMOX
- 21 Oct 2014 New trial record